NIAGEN BIOSCIENCE INC
NAGENASDAQ🏆 #3587 by market capUS Equity
$2.55▲ $0.00 (+0.00%)
Latest quoteTrack NAGE
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▲ 1.8%
14d▼ 1.2%
30d▼ 13.9%
ytd▼ 59.8%
1y▼ 64.9%
🏦Market Cap
$202M
Small Cap
📈Revenue Growth (YoY)
11.0%
Healthy
📊Gross Margin
64.2%
High
💵FCF Margin
5.4%
Moderate
⚖️P/S Ratio
1.6x
Cheap
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $2.54 – $2.58
- 52-Week Range
- $2.39 – $7.95
- Volume (shares)
- 10,555
- Avg Volume (shares)
- —
- Shares Outstanding
- 79.1M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $129M
- Last Q Revenue
- $30M
- P/E Ratio
- 12.5
- P/S Ratio
- 1.6x
- EPS (TTM)
- $0.19
- Dividend Yield
- —
- Dilution (1yr)
- +3.4%
NIAGEN BIOSCIENCE INC
NAGEFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$129M▲ +29.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
64.3%▲ +3.9% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$14M▲ +85.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$13M▲ +10.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
84.4M▲ +3.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$62M▲ +$20M YoY
StockOtter · stockotter.spaceAbout NIAGEN BIOSCIENCE INC
Niagen Bioscience Inc operates as a biotechnology enterprise with a core focus on promoting healthy aging. This company is also renowned for its pioneering research into nicotinamide adenine dinucleotide.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
12 analysts
Strong Buy4
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.